|Articles|July 12, 2023
Are Nitrosamines a Concern for Biologic Manufacturers
Author(s)SGS
This article provides an assessment of nitrosamine contamination specifically in biologics and contrasts the potential risks between these product types.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies
2
New Draft Guidance Highlights FDA Push Toward Human-Relevant Safety Models
3
Implementing Automation and Flexible Design for Allogeneic Manufacturing
4
Regulatory Uncertainty Surfaces as FDA Blames COVID Vaccines for 10 Child Deaths
5
